Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity, Inc.'s SEC filings document operating results, governance matters and capital-structure disclosures for a Massachusetts-incorporated life sciences and diagnostics company. Its 8-K reports furnish quarterly and annual financial results, preliminary performance updates, Regulation FD investor presentation materials and other material-event disclosures.
Proxy and annual-meeting filings describe director elections, auditor ratification, advisory executive-compensation votes and shareholder-approved bylaw amendments, including the ability of holders of 25% of the company's stock to call a special meeting. Other current reports identify registered securities, including RVTY common stock and 1.875% notes due 2026 listed on the New York Stock Exchange, as well as officer appointments and related governance changes.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting beneficial ownership of 10,097,663 shares of Revvity Inc. common stock, representing 9.0% of the class. The filing shows sole voting power for 10,019,315 shares and sole dispositive power for 10,097,663 shares. The amendment is signed by Ellen York, Vice President, on 05/15/2026.
Revvity, Inc. reported first-quarter fiscal 2026 revenue of $711.1 million, up 7% from $664.8 million a year earlier, with growth in both Life Sciences and Diagnostics and an extra fiscal week contributing. Life Sciences revenue rose to $361.8 million and Diagnostics to $349.3 million.
Gross margin narrowed from 56.5% to 54.5%, pressured by product mix, foreign exchange, higher tariffs and the extra week. Net income was $40.7 million, compared with $42.2 million, and diluted EPS was $0.36. Operating cash flow from continuing operations was $125.9 million, supporting ongoing share repurchases and dividends.
The company closed the $72 million acquisition of Advanced Chemistry Development Inc., recording $32.0 million of goodwill, and booked $10.7 million in restructuring and other costs tied to workforce reductions and facility consolidations affecting about 2% of employees. Revvity ended the quarter with $860.3 million in cash and cash equivalents and total debt of about $3.23 billion, while continuing to return capital through a $0.07 per share quarterly dividend and $79.0 million of stock buybacks under its $1.0 billion repurchase program.
REVVITY, INC. director Alexis P. Michas reported equity-based compensation and indirect holdings in the company’s common stock. On May 7, 2026, he acquired 1,467 shares through a grant of restricted stock units and an additional 1,217 shares as a separate award, both at $0.00 per share as non-cash compensation. The restricted stock units each represent one share of common stock and are scheduled to fully vest on April 27, 2027, the date of the company’s next annual shareholder meeting, subject to his continued service or earlier vesting upon death, disability, qualifying retirement, or certain change-in-control terminations. Following these awards, his direct holdings reported in this filing include over 60,000 shares. He also reports 7,270 shares held indirectly through The Cayre and Alexis Michas Foundation Corp. and 500 shares held in his spouse’s IRA. The foundation is a charitable vehicle, and he disclaims beneficial ownership of those foundation-held shares except to the extent of any pecuniary interest.
REVVITY, INC. director Sophie V. Vandebroek reported two stock-based compensation awards. She acquired 1,265 and 1,015 restricted stock units, each unit representing one share of common stock granted at no cash cost.
The restricted stock units will fully vest on April 27, 2027, the scheduled date of the next annual meeting of shareholders, if she continues to serve through that date. Vesting can also occur earlier in cases such as death, disability, qualifying retirement, or certain terminations within 12 months after a change in control.
REVVITY, INC. director Michael A. Klobuchar reported compensation-related equity awards, not open-market trading. On May 7, 2026, he received two grants of common-stock-based awards for 1,265 and 1,015 shares. These are restricted stock units that each convert into one share and are scheduled to fully vest on April 27, 2027, subject to his continued service or earlier vesting upon death, disability, qualifying retirement, or certain change-in-control related terminations.
Witney Frank reported acquisition or exercise transactions in this Form 4 filing.
REVVITY, INC. director Frank Witney reported two stock-based compensation grants in the form of restricted stock units tied to the company’s common stock. He was awarded 1,265 units and 1,015 units, each at no cash cost, reflecting equity compensation rather than open-market buying.
Each restricted stock unit represents the right to receive one share of common stock if vesting conditions are met. The units are scheduled to fully vest on April 27, 2027, aligned with the company’s next annual meeting of shareholders, subject to his continued service or earlier vesting upon specified events such as death, disability, qualifying retirement, or certain post–change-in-control terminations.
REVVITY, INC. director Samuel R. Chapin reported stock-based compensation awards rather than open‑market trades. On May 7, 2026, he acquired 1,265 shares of common stock at a price of $0.00 per share through a grant classified as a restricted stock unit award. The filing also shows a second grant of 1,015 common shares at $0.00 per share, reflecting additional equity compensation.
The restricted stock units will fully vest on April 27, 2027, the scheduled date of the company’s next annual meeting of shareholders, as long as Chapin continues in service. They may vest earlier upon death, disability, qualifying retirement, or if his service ends within 12 months following a change in control.
REVVITY, INC. director Michel Vounatsos reported receiving two equity awards of common stock on May 7, 2026, each recorded as a grant or award acquisition. The awards cover 1,265 and 1,015 shares at no cash cost to him.
According to a footnote, these awards are in the form of restricted stock units, each representing a contingent right to one share of common stock. The units are scheduled to fully vest on April 27, 2027, the date of the next annual shareholder meeting, subject to his continued service or earlier vesting upon death, disability, qualifying retirement, or certain terminations within 12 months after a change in control.
McMurry-Heath Michelle reported acquisition or exercise transactions in this Form 4 filing.
REVVITY, INC. director Michelle McMurry-Heath reported equity compensation awards in the form of common stock. On May 7, 2026, she received grants of 1,265 and 1,015 restricted stock units, each representing a contingent right to one share of common stock.
The restricted stock units will fully vest on April 27, 2027, the scheduled date of Revvity’s next annual meeting of shareholders, provided she continues serving through that date. Vesting may also occur earlier in limited cases such as death, disability, qualifying retirement, or termination within 12 months following a change in control.
Witz Pascale reported acquisition or exercise transactions in this Form 4 filing.
REVVITY, INC. director Pascale Witz reported two equity awards of common stock, recorded as grants or awards rather than open-market purchases. The filing shows 1,265 shares and 1,015 shares were granted at a price of $0.00 per share as part of compensation.
These awards are in the form of restricted stock units, each representing a contingent right to receive one share of common stock. The restricted stock units are scheduled to fully vest on April 27, 2027, the date of the next annual meeting of shareholders, subject to continued service or certain earlier events such as death, disability, qualifying retirement, or specified post–change in control termination.